SCHEDULE: Millennium Management Amends Fulgent Genetics Stake, Reports 4.7% Beneficial Ownership

Millennium Management LLC and its affiliates have filed an Amendment No. 2 to their Schedule 13G, disclosing a 4.7% beneficial ownership stake in Fulgent Genetics, Inc. as of June 30, 2025.

Summary

• Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have filed an Amendment No. 2 to their Schedule 13G regarding their beneficial ownership of Fulgent Genetics, Inc. Common Stock.
• As of June 30, 2025, the reporting persons collectively beneficially own 1,442,262 shares of Fulgent Genetics, Inc. Common Stock.
• This represents 4.7% of the class of outstanding Common Stock.
• The filing states that Integrated Core Strategies (US) LLC, an affiliate of the reporting persons, became the beneficial owner of more than 5% of the outstanding Common Stock on July 22, 2025.
• The filing also contains a conflicting statement that, as of the filing date, the reporting persons are beneficial owners of more than 5% of the outstanding Common Stock, despite the cover page reporting 4.7%.
• The securities are held by entities subject to voting control and investment discretion by Millennium Management LLC and/or other investment managers controlled by Millennium Group Management LLC and Israel A. Englander.
• The acquisition of these securities was not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: The filing is a standard beneficial ownership disclosure and does not contain information that would significantly alter the sentiment towards the company's operational or financial performance. The slight inconsistency in reported percentage is noted but does not drastically change the overall neutral sentiment.

Positives

• A significant institutional investor, Millennium Management, maintains a substantial stake in Fulgent Genetics, indicating continued interest in the company.

Negatives

• The reported beneficial ownership percentage of 4.7% is below the 5% threshold typically associated with Schedule 13G filings, which could imply a reduction in stake from a previous filing, although the filing text contains a conflicting statement that the reporting persons own more than 5%.
• There is an inconsistency between the reported 4.7% beneficial ownership on the cover page and the narrative statement in Item 4(a) claiming beneficial ownership of more than 5% as of the filing date, which could lead to confusion.

Risks

• The filing does not indicate any specific risks related to Fulgent Genetics, Inc. or its operations, as it is a beneficial ownership disclosure.

Future Outlook

This filing does not provide any forward-looking statements or guidance regarding the issuer's future performance or outlook.

Industry Context

This filing is a routine disclosure of beneficial ownership by an institutional investor in a genetics company. It does not provide insights into broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional ownership and changes in stake, which can influence market perception and liquidity.

Key Dates

Keywords

Fulgent Genetics, Millennium Management, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Investor, FGHT, Genetics, Biotechnology